Get informed when a big investor buys or sells
+ Follow-9.43%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Vectus Biosystems Limited (VBS.AX) currently reports a ROE of -9.43%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Vectus Biosystems Limited's ROE history and peer comparisons.
Vectus Biosystems Limited's ROE of -9.43% is lower than the Healthcare sector average of 13.1%. That is roughly 171.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Vectus Biosystems Limited's current -9.43% should be judged against Healthcare norms (sector average: 13.1%) and against VBS.AX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -9.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Vectus Biosystems Limited, and consider following VBS.AX for alerts when major investors trade the stock.
Vectus Biosystems Limited is classified in the Healthcare sector. On ROE, it currently shows -9.43% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VBS.AX with unrelated industries.